Skip to main content

Human Papillomavirus: Vaccination

Question for Department of Health

UIN 5682, tabled on 6 July 2015

To ask the Secretary of State for Health, if he will make an assessment of the implications for his Department's policies of the steps taken by the Danish government to examine people suspected of having a negative reaction to HPV vaccines.

Answered on

9 July 2015

The Joint Committee on Vaccination and Immunisation (JCVI), the expert committee that advises Ministers on immunisation related issues, considered the safety of the human papillomavirus (HPV) vaccine in June 2015. It considered reports made to the Medicines and Healthcare products Regulatory Agency and also published literature. It concluded that it had no concerns about the safety of the HPV vaccine. The JCVI strongly supported continued use of the HPV vaccine to prevent infection with HPV and reduce cases of cervical cancer and other HPV associated cancers. The minutes of the meeting will be published later in the year.

European regulators are aware of the reports emerging from Denmark, including reports of Postural Orthostatic Tachycardia Syndrome, and these remain under review. At this time the evidence does not support a causative link between HPV vaccination and Postural Orthostatic Tachycardia Syndrome.

The safety of HPV vaccines remain under continual review and appropriate action will be taken if any important new risks are confirmed.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.